Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, ...

Good morning to those of you here in the room, and also good morning to those of you joining us virtually today. On behalf of the Coloplast management team and on behalf of Investor Relations, I would ...

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral ...

Good morning, ladies and gentlemen, and welcome to Coloplast interim financial statements for the first 9 months for 2024-2025. [Operator Instructions] This conference will be recorded. [Operator ...

Investing.com -- Coloplast A/S (CSE: COLOb) on Tuesday said its net profit fell 26% in the first nine months of its 2024/25 financial year, as extraordinary tax expenses tied to its Kerecis unit ...

On Monday, Barclays (LON:BARC) analysts downgraded Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) stock rating from Overweight to Equalweight and reduced the price target to DKK750.00 from DKK1,010 ...

(Bloomberg) — Coloplast A/S fired its chief executive officer to restore investor confidence after the medical equipment maker failed to deliver sufficient shareholder returns. That’s according to ...

On Monday, Deutsche Bank analysts adjusted their stance on Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), downgrading the medical device company’s stock rating from Buy to Hold. Accompanying this ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

Organic Growth: 8% for the full year '23-'24. EBIT Margin Before Special Items: 27% for the full year '23-'24. Return on Invested Capital: 15% after tax and before special items. Revenue Increase: DKK ...

Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. "We have entered the final year of our 2025 strategy. In this strategic period ...